Evaluation of Alisertib Alone or Combined with Fulvestrant in Patients with Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial

Tufia C. Haddad, Vera J. Suman, Antonino B. D'Assoro, Jodi M. Carter, Karthik V. Giridhar, Brendan P. McMenomy, Katelyn Santo, Erica L. Mayer, Meghan S. Karuturi, Aki Morikawa, P. Kelly Marcom, Claudine J. Isaacs, Sun Young Oh, Amy S. Clark, Ingrid A. Mayer, Khandan Keyomarsi, Timothy J. Hobday, Prema P. Peethambaram, Ciara C. O'Sullivan, Roberto A. Leon-FerreMinetta C. Liu, James N. Ingle, Matthew P. Goetz

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Evaluation of Alisertib Alone or Combined with Fulvestrant in Patients with Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences